ANNAPOLIS, Md., June 12 /PRNewswire/ -- PharmAthene, Inc., a leading biodefense company focused on the development and commercialization of medical countermeasures to combat bioterrorism, presented data last week at the Bioscience Review 2006 meeting, outlining a newly-developed manufacturing process to facilitate commercial-scale production of the Company’s recombinant human butyrylcholinesterase product, Protexia®.
